News >

Frontline Pembrolizumab Combo Improves Survival in Phase III NSCLC Trial

Jason M. Broderick @jasoncology
Published: Tuesday, Jan 16, 2018

Roger M. Perlmutter, MD, PhD
Roger M. Perlmutter, MD, PhD
Combining pembrolizumab (Keytruda) with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer (NSCLC), according to findings from the phase III KEYNOTE-189 trial. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication